Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

(2010) A. J. Tyndall et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

(2009) O Kowal-Bielecka et al.   ANNALS OF THE RHEUMATIC DISEASES

Interstitial Lung Disease in Systemic Sclerosis

(2008) Nicole S. L. Goh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

(2008) Carlotta Nannini et al.   ARTHRITIS RESEARCH & THERAPY

Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease

(2007) Charlie Strange et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE